Aquestive Therapeutics, Inc. (AQST)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$4.57+0.44%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $574M
- 52-week range
- $2.93 – $7.55
- 52-week change
- −23.79%
- EPS (trailing)
- −$0.66
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $44.5M (−22.61%)
- Net income
- −$83.8M
- Operating margin
- −159.5%
- Diluted EPS
- −$0.78
- Free cash flow
- −$53.0M
From the company’s annual report on SEC EDGAR.
About Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform.
Headquarters: Warren, United States · 147 employees · aquestive.com